Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies.

ABSTRACT:

Background

Immune checkpoint and BRAF-targeted inhibitors have demonstrated significant survival benefits for advanced melanoma patients within the context of clinical trials. We sought to determine their impact on overall survival (OS) at a population level in order to better understand the current landscape for patients diagnosed with clinical stage III melanoma.

Methods

A retrospective study was performed using the National Cancer Database. Patients diagnosed with clinical stage III melanoma were categorized by diagnosis year into two cohorts preceding the advent of novel therapies (P1: 2004-2005, P2: 2008-2009) and a contemporary group (P3: 2012-2013). OS was estimated using standard time-to-event statistical methods.

Results

Of 3720 patients, 525 (14%) were diagn

SUBMITTER: Song Y 

PROVIDER: S-EPMC8740891 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature